Pipeline
VAN-01 / lead NKEV candidate Pancreatic cancer. Preclinical Pancreatic cancer appears in current NCI-facing and roadmap materials.
NKEV program GBM Preclinical GBM is listed among lead strategic indications.
NKEV program Multiple myeloma Preclinical foundation established. Historic core indication under STTR work and earlier deck positioning.
NKEV program TNBC Discovery / preclinical. Included in company materials as a focus area.
NKEV program Refractory hematologic/solid tumors Platform expansion. Use broad language until indication-specific packages mature.
The pipeline reflects ongoing prioritization based on translational data, regulatory strategy, and manufacturing readiness.
Our principal translational development partner in Alabama. Southern Research’ has the full capability to study NK EV test articles and assess in vivo toxicity, with GLP-compliant facilities and broad oncologic and therapeutic development experience. Vanquish is a recipient of Southern Research' Therapeutics Development Fund, which was launched using Innovate Alabama-backed support and has funded biotech company growth in Alabama.
.avif)
Statewide innovation support that helped accelerate translational milestones. Reflects ties the Alabama presence to Southern Research and Station 41 activity.
Federal non-dilutive support for development of NK cell-derived extracellular vesicles as a new treatment for cancer. The SBIR/STTR portfolio lists Vanquish Bio’s 2022 NCI award of $399,580 and describes the program goal as developing potent NK EV preparations with anti-tumor activity and low toxicity.
Confidential CDMO Partner
Vanquish Biologics is working with an active manufacturing partner under confidentiality to support scalable process transfer and GMP-grade clinical supply planning. Keep this short, because unnamed partners raise questions if overplayed.